Asabys announces the first close of its fund, with commitments of €100M – #BHHMembersInitiatives

BHH member Asabys has announced today the 1st closing of its new fund, Sabadell Asabys Health Innovation Investments II (SAHII II), with total commitments of 100 million euros, expecting to reach a size of €200 million this year. SAHII II will invest in healthtech and biopharma companies, that provide novel solutions to unmet medical needs, with solid scientific evidence, and a clear benefit for patients.

This new fund consolidates Asabys launch back in 2018, investing mainly in the EU, UK, Israel and the US, with a special focus in Spain, and corroborates the market interest for Asabys’ hybrid investment model, that ranges from biopharmaceutical projects to digital solutions, including advanced diagnostic tools and medical devices. Asabys announces this first closing only 6 months after the launch of the fund.

Clara Campas comments: “After 4 years since launch, this first closing consolidates us as a firm, and reaffirms investors’ growing interest for private investment in healthcare”. Josep Ll. Sanfeliu adds: “This new fund represents a consolidation of our investment strategy, aimed at exceeding €500 million in assets under management in the coming years, with the aim of transforming the cutting-edge science of our research centers into disruptive and effective solutions, facing the challenges that we currently have in areas such as oncology, neurology and cardiovascular.”

Asabys has reinforced its team of professionals with new incorporations and has appointed Sylvain Sachot and Guillem Masferrer as partners, both with extensive experience as venture capital investors in the life sciences and healthcare industries, who have been part of the firm since inception.

Sylvain Sachot has a PhD in Molecular Biology from the University of Nantes and an MBA from ESADE. He worked for a decade in academic laboratories such as INSERM (France) and the Mount Sinai School of Medicine (New York), researching in the field of gene therapy and regenerative medicine. Sylvain has an extensive experience in venture capital, having invested in Biotech and MedTech companies worldwide.

Guillem Masferrer, BsC in Business Administration by UPF, has 8 years of experience in healthcare venture capital. Guillem has led the construction of Asabys’ digital health portfolio, currently comprised by 4 companies, helping position the firm as one of the leading European investors in digital health.